|
1
|
Holmes C: Review: systemic inflammation
and Alzheimer’s disease. Neuropathol Appl Neurobiol. 39:51–68.
2013. View Article : Google Scholar
|
|
2
|
Sundelof J, Kilander L, Helmersson J, et
al: Systemic inflammation and the risk of Alzheimer’s disease and
dementia: a prospective population-based study. J Alzheimers Dis.
18:79–87. 2009.
|
|
3
|
Kaltschmidt C, Kaltschmidt B,
Lannes-Vieira J, et al: Transcription factor NF-kappa B is
activated in microglia during experimental autoimmune
encephalomyelitis. J Neuroimmunol. 55:99–106. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ekdahl CT, Kokaia Z and Lindvall O: Brain
inflammation and adult neurogenesis: the dual role of microglia.
Neuroscience. 158:1021–1029. 2009. View Article : Google Scholar
|
|
5
|
Kim YS and Joh TH: Microglia, major player
in the brain inflammation: their roles in the pathogenesis of
Parkinson’s disease. Exp Mol Med. 38:333–347. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Grilli M and Memo M: Nuclear
factor-kappaB/Rel proteins: a point of convergence of signalling
pathways relevant in neuronal function and dysfunction. Biochem
Pharmacol. 57:1–7. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jobin C, Morteau O, Han DS and Balfour
Sartor R: Specific NF-kappaB blockade selectively inhibits tumour
necrosis factor-alpha-induced COX-2 but not constitutive COX-1 gene
expression in HT-29 cells. Immunology. 95:537–543. 1998. View Article : Google Scholar
|
|
8
|
Chen LF and Greene WC: Shaping the nuclear
action of NF-kappaB. Nat Rev Mol Cell Biol. 5:392–401. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen L, Fischle W, Verdin E and Greene WC:
Duration of nuclear NF-kappaB action regulated by reversible
acetylation. Science. 293:1653–1657. 2001. View Article : Google Scholar
|
|
10
|
Greene WC and Chen LF: Regulation of
NF-kappaB action by reversible acetylation. Novartis Found Symp.
259:208–225. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Choi KC, Jung MG, Lee YH, et al:
Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor,
inhibits EBV-induced B lymphocyte transformation via suppression of
RelA acetylation. Cancer Res. 69:583–592. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim MJ, Seong AR, Yoo JY, et al: Gallic
acid, a histone acet-yltransferase inhibitor, suppresses β-amyloid
neurotoxicity by inhibiting microglial-mediated neuroinflammation.
Mol Nutr Food Res. 55:1798–1808. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Seong AR, Yoo JY, Choi K, et al:
Delphinidin, a specific inhibitor of histone acetyltransferase,
suppresses inflammatory signaling via prevention of NF-κB
acetylation in fibroblast-like synoviocyte MH7A cells. Biochem
Biophys Res Commun. 410:581–586. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Duclot F, Jacquet C, Gongora C and Maurice
T: Alteration of working memory but not in anxiety or stress
response in p300/CBP associated factor (PCAF) histone acetylase
knockout mice bred on a C57BL/6 background. Neurosci Lett.
475:179–183. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Choi KC, Lee YH, Jung MG, et al: Gallic
acid suppresses lipopolysaccharide-induced nuclear factor-kappaB
signaling by preventing RelA acetylation in A549 lung cancer cells.
Mol Cancer Res. 7:2011–2021. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Park SY, Lee YH, Seong AR, Lee J, Jun W
and Yoon HG: Selective inhibition of PCAF suppresses
microglial-mediated β-amyloid neurotoxicity. Int J Mol Med.
32:469–475. 2013.PubMed/NCBI
|
|
17
|
Bae D, Kim Y, Kim J, et al:
Neuroprotective effects of Eriobotrya japonica and Salvia
miltiorrhiza Bunge in in vitro and in vivo models. Animal Cells
Systems. 18:119–134. 2014. View Article : Google Scholar
|
|
18
|
Vincent D, Segonzac G and Vincent MC:
Colorimetric determination of acetylcholine by the Hestrin
hydroxylamine reaction and its application in pharmacy. Ann Pharm
Fr. 16:179–185. 1958.In French. PubMed/NCBI
|
|
19
|
Ellman GL, Courtney KD, Andres V Jr and
Feather-Stone RM: A new and rapid colorimetric determination of
acetylcholines-terase activity. Biochem Pharmacol. 7:88–95. 1961.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Das UN: Acetylcholinesterase and
butyrylcholinesterase as possible markers of low-grade systemic
inflammation. Med Sci Monit. 13:RA214–RA221. 2007.PubMed/NCBI
|
|
21
|
Kaltschmidt B, Uherek M, Volk B, Baeuerle
PA and Kaltschmidt C: Transcription factor NF-kappaB is activated
in primary neurons by amyloid beta peptides and in neurons
surrounding early plaques from patients with Alzheimer disease.
Proc Natl Acad Sci USA. 94:2642–2647. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Boissiere F, Hunot S, Faucheux B, et al:
Nuclear translocation of NF-kappaB in cholinergic neurons of
patients with Alzheimer’s disease. Neuroreport. 8:2849–2852. 1997.
View Article : Google Scholar
|
|
23
|
Lukiw WJ and Bazan NG: Strong nuclear
factor-kappaB-DNA binding parallels cyclooxygenase-2 gene
transcription in aging and in sporadic Alzheimer’s disease superior
temporal lobe neocortex. J Neurosci Res. 53:583–592. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Akama KT, Albanese C, Pestell RG and Van
Eldik LJ: Amyloid beta-peptide stimulates nitric oxide production
in astrocytes through an NFkappaB-dependent mechanism. Proc Natl
Acad Sci USA. 95:5795–5800. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang J, Zhen YF, Pu Bu Ci R, et al:
Salidroside attenuates beta amyloid-induced cognitive deficits via
modulating oxidative stress and inflammatory mediators in rat
hippocampus. Behav Brain Res. 244:70–81. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Memet S: NF-kappaB functions in the
nervous system: from development to disease. Biochem Pharmacol.
72:1180–1195. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Meffert MK, Chang JM, Wiltgen BJ, Fanselow
MS and Baltimore D: NF-kappa B functions in synaptic signaling and
behavior. Nat Neurosci. 6:1072–1078. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Albensi BC and Mattson MP: Evidence for
the involvement of TNF and NF-kappaB in hippocampal synaptic
plasticity. Synapse. 35:151–159. 2000. View Article : Google Scholar
|
|
29
|
Yeh SH, Lin CH, Lee CF and Gean PW: A
requirement of nuclear factor-kappaB activation in fear-potentiated
startle. J Biol Chem. 277:46720–46729. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Freudenthal R, Boccia MM, Acosta GB, et
al: NF-kappaB transcription factor is required for inhibitory
avoidance long-term memory in mice. Eur J Neurosci. 21:2845–2852.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Merlo E, Freudenthal R, Maldonado H and
Romano A: Activation of the transcription factor NF-kappaB by
retrieval is required for long-term memory reconsolidation. Learn
Mem. 12:23–29. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Malmsten L, Vijayaraghavan S, Hovatta O,
Marutle A and Darreh-Shori T: Fibrillar β-amyloid 1–42 alters
cytokine secretion, cholinergic signalling and neuronal
differentiation. J Cell Mol Med. 18:1874–1888. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Streit WJ: Microglia and neuroprotection:
implications for Alzheimer’s disease. Brain Res Brain Res Rev.
48:234–239. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tabet N: Acetylcholinesterase inhibitors
for Alzheimer’s disease: anti-inflammatories in acetylcholine
clothing! Age Ageing. 35:336–338. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Giunta B, Ehrhart J, Townsend K, et al:
Galantamine and nicotine have a synergistic effect on inhibition of
microglial activation induced by HIV-1 gp120. Brain Res Bull.
64:165–170. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nizri E, Irony-Tur-Sinai M, Faranesh N, et
al: Suppression of neuroinflammation and immunomodulation by the
acetylcho-linesterase inhibitor rivastigmine. J Neuroimmunol.
203:12–22. 2008. View Article : Google Scholar : PubMed/NCBI
|
